The improvement from baseline in the SGRQ score was 6.4 points and 7.0 points greater in the intravenous and subcutaneous mepolizumab groups , respectively , than in the placebo group ( minimal clinically important change , 4 points ) , and the improvement in the ACQ-5 score was 0.42 points and 0.44 points greater in the two mepolizumab groups , respectively , than in the placebo group ( minimal clinically important change , 0.5 points ) ( P < 0.001 for all comparisons ) .